Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. Review uri icon

Overview

abstract

  • Adoptive T-cell therapy with chimeric antigen receptor T cells (CAR-Ts) has produced impressive clinical responses among patients with B-cell malignancies, and several groups have published positive results using anti-CD19 CAR-Ts for the treatment of B-cell acute lymphoblastic leukemia. Recently, new data from clinical trials have demonstrated the benefits of CAR-T therapy in the non-Hodgkin's lymphoma (NHL) setting. This review describes some of the most recent and promising advances in engineered T-cell therapy, with particular emphasis on the clinical benefits of NHL treatment.

publication date

  • November 1, 2017

Research

keywords

  • Antigens, CD19
  • Antigens, Neoplasm
  • Immunotherapy, Adoptive
  • Lymphoma, Non-Hodgkin
  • Receptors, Antigen, T-Cell
  • T-Lymphocytes

Identity

Scopus Document Identifier

  • 85033778744

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2017.7045

PubMed ID

  • 29118234

Additional Document Info

volume

  • 15

issue

  • 11